G protein-coupled receptors (GPCRs) represent the targets of more than 30% of the drugs currently on the market. However, ...

A new global systematic review and meta-analysis has found that overusing short-acting beta-agonist (SABA) inhalers-commonly ...

Research on the Digihaler highlights its potential to track COPD inhaler use, offering real-world data to improve treatment ...

Region residents are no strangers to tricky weather, well-accustomed to everything from winter snowstorms and deep freezes to ...

A pilot study shows digital inhaler data can detect early signs of COPD exacerbations, offering promise for proactive disease ...

The combination of the inhaled corticosteroid (budesonide) and short-acting beta-2 adrenergic agonist (albuterol sulfate) is FDA approved for as-needed use in adults with asthma based on the ...

No Salbutamol will not damage your heart - it has side effects of causing palpitations but this is just due to the specific receptors it targets. Gold standard treatment is actually to be on a long ...

Cornell University. "COPD Patients Using Beta-agonist Inhalers Are At Risk." ScienceDaily. ScienceDaily, 8 July 2006. <www.sciencedaily.com / releases / 2006 / 07 / 060708082822.htm>.

It should be noted that the number of patients starting inhaled maintenance therapy dropped to 27,109 in 2020 but went back up in 2021 with 31,658 patients and in 2022 with 32,558 patients.

1.7.7 Change treatment for people with confirmed asthma who are currently using a short-acting beta 2 agonist (SABA) only to a low-dose ICS/formoterol combination inhaler used as needed (as-needed AIR ...

There are several types of medications used in inhalers and nebulizers, including beta agonists, muscarinic agonists or anticholinergics, and corticosteroids, as well as combined medications.

Pharmacological treatment 1.6.2 Do not prescribe short-acting beta2 agonists to people of any age with asthma without a concomitant prescription of an inhaled corticosteroid (ICS). [2024] 1.7.1 Offer ...